Upwards Drift of Cerebrospinal Fluid Amyloid-β 42 Over Twelve Years in a Consecutive Clinical Cohort

Article type: Short Communication

Authors: Simonsen, Anja Hviid^{a; *} | Musaeus, Christian Sandøe^a | Christensen, Gitte Lund^b | Hasselbalch, Steen Gregers^a | Waldemar, Gunhild^a

Affiliations: [a] Danish Dementia Research Centre, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark | [b] Centre of Diagnostic Investigations, Department of Clinical Chemistry, Rigshospitalet Glostrup, University of Copenhagen, Copenhagen, Denmark

Correspondence: [*] Correspondence to: Anja Hviid Simonsen, Danish Dementia Research Centre, Rigshospitalet, section 8007, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. Tel.: +45 3545 1804; E-mail: anja.hviid.simonsen@regionh.dk.

Abstract: Amyloid-β 1–42 (Aβ1–42) measured in the cerebrospinal fluid (CSF) can be used as a diagnostic biomarker for Alzheimer’s disease (AD) but an upward drift when using the INNOTEST ELISA has been suggested. We investigated the upwards drift of Aβ1–42 levels over a period of twelve years in a consecutive memory clinic cohort. We found a significant increase in Aβ1–42 from 2008 to 2019 independent of changes in tau. New methods for the quantification of CSF Aβ1–42 levels are being implemented but awareness of this upwards drift is crucial during the diagnostic work-up and when selecting historical samples for research.

Keywords: Alzheimer’s disease, amyloid-β 42, biomarker, cerebrospinal fluid

DOI: 10.3233/JAD-201506

Journal: Journal of Alzheimer's Disease, vol. 81, no. 4, pp. 1369-1373, 2021